Which groups of people are not suitable to take Tazetostat (Daveko) and risk warnings

Tazemetostat (Tazemetostat) is an oral EZH2 inhibitor, mainly used to treat relapsed or refractory follicular lymphoma and epithelial sarcoma. It exerts anti-tumor effects by inhibiting the activity of histone methyltransferase EZH2, blocking tumor cell proliferation and promoting apoptosis. However, not all patients are suitable for use. The drug has potential risks in some people and needs to be used with caution under the guidance of a doctor.

Pregnant and lactating women should not use tazetostat. Medications may be potentially toxic to the fetus or infant, causing developmental abnormalities or birth defects. Therefore, female patients should take effective contraceptive measures during treatment, follow medical advice to delay pregnancy after stopping the drug, and avoid breastfeeding. Male patients also need to use contraceptive measures to prevent the drug from affecting reproductive health through sperm.

Patients with severely impaired liver function should use this medication with caution. Tazerestat is mainly metabolized by the liver. Liver dysfunction may lead to drug accumulation in the body and increase the risk of toxic side effects, such as hematological abnormalities and elevated liver enzymes. Before use, liver function should be assessed, and the dose should be adjusted or the dosing interval extended according to the doctor's recommendations to ensure safety.

Patients with abnormal hematological indicators or a history of myelosuppression also need to be careful. Tazerestat may cause neutropenia, anemia, or thrombocytopenia and increase the risk of infection and bleeding. During the treatment process, blood routine should be monitored regularly, and the dose should be adjusted or the drug temporarily discontinued based on the results. Patients with other serious comorbidities should also weigh the pros and cons under the guidance of a doctor and use drugs with caution.

Reference materials:https://www.drugs.com/